Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The CLL Channel

Explore the latest updates, including expert interviews, features, podcasts and e-learning

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Latest Videos The CLL Sessions Conferences Topics Features Podcasts Expert Editorial Board

Welcome to The Chronic Lymphocytic Leukemia (CLL) Channel

The CLL Channel delivers exciting and topical research in CLL via video interviews, podcasts, roundtable discussions and more. Reporting from key international congresses with world-leading experts, VJHemOnc provides hot topics in CLL such as measurable residual disease (MRD) monitoring, prognostic biomarkers, CAR-T and updates on the use of BTK and BCL-2 inhibitors.

Conferences

ASH 2025
iwCLL 2025
SOHO 2025
EHA 2025
ASCO 2025
IBC 2025
0:53
Top updates in CLL from ASH 2025: insights into time-limited treatment from the CLL17 trial
Barbara Eichhorst • 7 Dec 2025
1:30
The RT1 trial of tislelizumab plus zanubrutinib for the treatment of Richter’s transformation
Barbara Eichhorst • 7 Dec 2025
1:38
An ongoing Phase II dose-optimization trial of pirtobrutinib in patients with CLL/SLL
Alexey Danilov • 6 Dec 2025
2:04
The Phase II TaZa CLL study of tafasitamab plus zanubrutinib in newly diagnosed CLL
Alexey Danilov • 6 Dec 2025
View All Videos
2:34
The IMPROVE trial: paused versus continuous BTKi therapy during vaccination in patients with CLL
Helen Parry • 17 Oct 2025
2:51
Characteristics of patients with CLL who develop immunity following vaccination on BTKi therapy
Helen Parry • 17 Oct 2025
3:15
Managing patients with CLL who relapse after triplet therapy
Jacob Soumerai • 18 Sep 2025
1:29
The optimal duration of time-limited BTKi plus BCL2i combination therapies in CLL
Moritz Fürstenau • 13 Sep 2025
View All Videos
1:30
BTK degraders in CLL: how may these agents shape the field?
Nirav Niranjan Shah • 24 Sep 2025
1:56
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines
Nirav Niranjan Shah • 24 Sep 2025
3:24
Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study
Nirav Niranjan Shah • 24 Sep 2025
1:43
Advice for young investigators entering the CLL space and key areas of interest
Meghan Thompson • 4 Sep 2025
View All Videos
3:54
The uptake of targeted agents by race/ethnicity in patients receiving first-line treatment for CLL
Adam Kittai • 12 Jun 2025
2:18
Promising agents in the treatment of CLL: BTK degraders and novel BCL2 inhibitors
Jacqueline Barrientos • 19 Jun 2025
5:35
Fixed-duration versus continuous treatment of venetoclax-based regimens in CLL
Jacqueline Barrientos • 19 Jun 2025
1:58
Recent developments in the treatment of Richter’s transformation
Adam Kittai • 12 Jun 2025
View All Videos
1:10
The combination of sonrotoclax and zanubrutinib in MCL and CLL
Constantine Tam • 31 May 2025
2:57
Highlights in NHL and CLL from ASCO 2025: key trial updates
Manali Kamdar • 1 Jun 2025
1:20
Final analysis of the CAPTIVATE study and comparisons with the SEQUOIA trial
Constantine Tam • 31 May 2025
2:12
Five-year follow-up of SEQUOIA Arm C: zanubrutinib in patients with del(17p) CLL
Constantine Tam • 31 May 2025
View All Videos
1:36
Novel testing approaches for the early detection of suspected lymphoproliferative disorders
Anton Langerak • 14 Mar 2025
1:11
The development of new tools to explore the biology of malignant transformation
Sandrine Roulland • 14 Mar 2025
2:11
Understanding the cell of origin and BCR function in CLL
Hendrik Veelken • 14 Mar 2025
1:29
The potential for early interception in MBL: advances and barriers
Anton Langerak • 14 Mar 2025
View All Videos

Topics

MRD
CAR-T & Cellular Therapy
Community Focus
Transplant
Immuno-Oncology
Disease Biology
6:14
Zanubrutinib, obinutuzumab, and sonrotoclax in patients with treatment-naive CLL
Jacob Soumerai • 17 Dec 2025
9:23
CLL17 trial: fixed-duration vs continuous targeted treatment for previously untreated CLL
Othman Al-Sawaf • 6 Dec 2025
7:15
MRD-guided treatment with ibrutinib and other agents in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
2:08
Fixed-duration and MRD-adapted therapy in CLL: insights from ASH 2025
Matthew Davids • 8 Dec 2025
View All Videos
1:15
Genetic and metabolic drivers of Richter’s transformation
Elisa ten Hacken • 8 Dec 2025
1:21
Developing and testing a tandem CD19/ROR1 CAR-NK to overcome apoptotic resistance in CLL
Matthew Davids • 8 Dec 2025
3:36
huCART19-IL18 in patients with CLL/SLL or RT after prior BTK inhibitor and venetoclax exposure
Jakub Svoboda • 7 Dec 2025
1:18
Immune exhaustion impacts CAR T-cell efficacy in Richter’s transformation
Frederick Locke • 7 Dec 2025
View All Videos
1:15
Treatment options for patients with CLL who have developed resistance to covalent BTK inhibitors
Paolo Ghia • 8 Dec 2025
9:23
CLL17 trial: fixed-duration vs continuous targeted treatment for previously untreated CLL
Othman Al-Sawaf • 6 Dec 2025
1:28
Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL
Tara Graff • 8 Dec 2025
3:43
Preventing infectious complications in patients with CLL: vaccination and social behaviors
Carsten Niemann • 5 Dec 2025
View All Videos
2:12
The unmet needs for patients with CLL in the UK and beyond
Nicolas Martinez-Calle • 14 Sep 2025
1:23
The role of transplantation and CAR-T in the treatment of Richter’s transformation
Michel van Gelder • 31 Mar 2025
2:44
The effectiveness of alloSCT after pathway inhibitor treatment in CLL
Michel van Gelder • 31 Mar 2025
2:10
The status of CAR T-cell therapy in acute and chronic leukemias
Ulrich Jäger • 7 Feb 2025
View All Videos
1:30
The RT1 trial of tislelizumab plus zanubrutinib for the treatment of Richter’s transformation
Barbara Eichhorst • 7 Dec 2025
2:04
The Phase II TaZa CLL study of tafasitamab plus zanubrutinib in newly diagnosed CLL
Alexey Danilov • 6 Dec 2025
1:51
Targeted therapies that appear likely to impact CLL practice in the coming years
Matthew Davids • 8 Dec 2025
1:15
Treatment options for patients with CLL who have developed resistance to covalent BTK inhibitors
Paolo Ghia • 8 Dec 2025
View All Videos
1:43
Studying progression from CLL to Richter’s transformation in immunocompetent mouse models
Elisa ten Hacken • 8 Dec 2025
1:15
Genetic and metabolic drivers of Richter’s transformation
Elisa ten Hacken • 8 Dec 2025
1:00
Recent advancements in the understanding of Richter’s transformation
Elisa ten Hacken • 8 Dec 2025
3:03
POD36 as a prognostic marker and clinical tool in frontline CLL
Paul Hampel • 8 Dec 2025
View All Videos

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

Diamond Supporter

AstraZeneca

Platinum Supporter

AbbVie

Silver Supporter

BeOne Medicines Lilly

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

If you are interested in becoming a supporter of The Chronic Lymphocytic Leukemia Channel, please contact us.

The content of VJHemOnc is intended for healthcare professionals